Korro Bio (KRRO) 10% Owner LP Buys $559K of Stock
Key Points
- Lynx1 Capital Management LP increased its stake in Korro Bio by 3.38%, now owning 1,597,155 shares.
- The stock closed at $12.05 on October 22, 2026, but recently traded around $12.02, which is about 0.2% below the event close.
- Korro Bio is set to report its next earnings on November 12, 2026, following a series of insider sales earlier this year.
Since the trade, $KRRO is down 0.2% to date (from the $12.05 close on Oct 22, 2026).
Get Korro Bio text alerts
We text you when insiders, Congress, analysts or big funds move on $KRRO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Korro Bio, Inc. alert may contain errors. Disclosures
On October 22, 2026, Lynx1 Capital Management LP bought 52,175 shares of Korro Bio, Inc. (KRRO) at an average price of $10.72, totaling about $559,274.26. This purchase is part of a larger trend as the firm now holds 1,597,155 shares, reflecting a 3.38% increase in their ownership. The information comes from a Form 4 filing with the SEC.
KRRO
Korro Bio, Inc.
Lynx1 Capital Management LP vs. the S&P 500
Hypothetical returns from Lynx1 Capital Management LP's disclosed trades, not real profit or advice. How we model this.
What Changed in Lynx1 Capital Management's Korro Bio Position
Lynx1 Capital Management increased its position in Korro Bio by 52,175 shares, bringing its total to 1,597,155 shares. The recent buy indicates the firm's confidence in the company's future prospects. Korro Bio's stock closed at $12.05 on the same day, making the purchase price significantly lower than the market value at that time.
Other Institutional Activity in Korro Bio
Several other funds hold significant stakes in Korro Bio. Lynx1 Capital Management LP remains a major player with 1,538,296 shares worth about $18.5 million. NEA Management Company, LLC holds 1,297,893 shares valued at approximately $15.6 million, while Venrock Adviser, LLC has 1,009,500 shares worth around $12.1 million. These funds have not made recent changes to their positions, maintaining their investments as Korro Bio continues to develop its RNA editing platform.
Korro Bio, Inc. Stock Down 0.2%
Korro Bio shares recently traded at $12.02, a slight decrease from the closing price of $12.05 on October 22, 2026. This price is about 71.9% below its 52-week high of $42.70 but 131% above its 52-week low of $5.20. The stock is currently above its 50-day and 200-day moving averages, suggesting some stability in its recent performance.
Recent Earnings
Korro Bio reported trailing twelve-month revenue of $2,382,000 and a net loss with an EPS of -$9.88. The company is expected to announce its next earnings on November 12, 2026. This upcoming report will provide further insight into the company's financial health and operational progress.
Dividend
Korro Bio does not pay a dividend, as indicated by a dividend yield of 0%. This aligns with many biotech firms that often reinvest profits into research and development rather than distributing them to shareholders.
Insider Buying and Selling at Korro Bio, Inc.
In June 2026, several insiders sold shares of Korro Bio. Chief Operating Officer Todd Chappell sold 3,168 shares at an average price of $10.83, totaling approximately $34,309. These sales indicate a trend of insider selling, which may raise questions among investors about the company's future.
Analysts Set New Price Targets
On October 6, 2026, HC Wainwright & Co. reiterated a Buy rating for Korro Bio with a price target of $15.00. The consensus among analysts is a strong buy, with a target mean price of $20.20 based on ten analyst opinions. This positive outlook contrasts with the recent insider selling activity, as analysts remain optimistic about Korro Bio's potential.
About Korro Bio
Korro Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing genetic medicines through RNA editing. Its lead candidate, KRRO-121, targets hyperammonemia, a condition that can arise from liver dysfunction. The company's innovative approach to RNA editing positions it well within the growing biotech sector.
Bottom Line
Investors should watch for Korro Bio’s upcoming earnings report on November 12, 2026, for insights into its financial performance. The recent insider selling raises questions, but analyst ratings suggest confidence in the company's future. Lynx1 Capital Management's recent purchase reflects a strategic move as the firm increases its stake in Korro Bio amid these developments.
Related Filing Alerts
Source: Lynx1 Capital Management LP's Form 4 filing on $KRRO (Oct 22, 2026). Written by software, not financial advice. How we make alerts